CNTX (Context Therapeutics) ROCE %: -66.27% (As of Mar. 2026)


CNTX Context Therapeutics Inc CNTX
30 GF Score
Price $0.58
! 1 Warning Sign
View Full Analysis

What is Context Therapeutics ROCE %?

Context Therapeutics CNTX -10.14% 30 ROCE % is -66.27% as of Mar. 2026. GuruFocus rates CNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Context Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -66.27%.

Context Therapeutics  (NAS:CNTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Context Therapeutics ROCE % Related Terms

Context Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Context Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Context Therapeutics ROCE % Chart

Context Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -53.04 -35.84 -107.54 -55.80 -50.95

Context Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.72 -44.95 -54.48 -82.62 -66.27
CNTX
30GF Score
Context Therapeutics Inc CNTX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Context Therapeutics ROCE % Calculation

Context Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-39.703/( ( (98.127 - 2.748) + (68.494 - 8.02) )/ 2 )
=-39.703/( (95.379+60.474)/ 2 )
=-39.703/77.9265
=-50.95 %

Context Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-37.376/( ( (68.494 - 8.02) + (58.859 - 6.534) )/ 2 )
=-37.376/( ( 60.474 + 52.325 )/ 2 )
=-37.376/56.3995
=-66.27 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -66.27% mean?
Context Therapeutics (CNTX) has a ROCE % of -66.27% as of Mar. 2026.
Is Context Therapeutics' ROCE % too high?
Context Therapeutics' current ROCE % is -66.27%. Overall, Context Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' ROCE % compare to TARA and NVCT?
Context Therapeutics' ROCE % of -66.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Context Therapeutics's current ROCE % is -66.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current ROCE % of -66.27%. The current ROCE % is -66.27%. Context Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current ROCE % is -66.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Context Therapeutics Business Description

Other Exchanges 6K9:Germany
Address 2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
30GF Score

Get the complete analysis for CNTX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.58
Price